Eligible participants for the study will receive either the potential new treatment drug or a placebo, with the aim of testing the impact of the drug on slowing or stopping cognitive decline. The study will also help researchers gather further information about the drug’s long-term safety.
If you qualify for and decide to join the APOLLOE4 study, you may receive at no cost:
Interested in this study? Great! We just need to check a few things so we can let you know if you are eligible.
Participants need to:
Log in or Sign up and complete your user profile so we have some basic information to determine if this study is relevant for you.
Upload your DNA data to the Sano site. Then if you decide you would like us to, as part of the pre-screen survey we can check to see if you have the genetic variants which would make you eligible for this study.
Answer a few quick questions to check if you are eligible and let us know that you're happy for us to pass your data on to the study team.
If you have a question that is not covered here, please let us know - we’ll be happy to answer and to update these FAQs.
Whether or not you receive updates depends on the type of study. For studies run entirely on the Sano platform ‘Sano studies’ you will receive updates on the study in most circumstances - if you will not for any reason, we will make this clear.
For studies that are run in collaboration with external partners, we cannot always guarantee that you will receive updates, but we work hard with the partners to ensure that this is the case as much as possible.
If you change anything that affects your eligibility in this study after enrolling or being referred, this does not affect your status in the study because we use the eligibility information you provided at the time of referral/enrollment.